In article <3r21ve$aa0 at nyx10.cs.du.edu>, M writes:
>There are experimental therapies to
>reduce this reperfusion injury, however. Thrombolysis is being tried in
>human stroke patients and it appears promising; last winter a large
>European trial showed a significnat improvement. A large US trial is in
>the analysis stage, I think.
There are currently about 25 clinical trials in the United States and
Europe, testing various stroke therapies. These trials can be divided into
two groups: clot-busters versus neuroprotection. The former include
various anticoagulants (a big NIH funded trial is comparing coumadin and iv
heparin) and of course TPA and other clot-busters. The latter has several
categories: antagonists of glutamate receptors, adenosine uptake
inhibitors, free radical scavengers (including superoxide dysmutase).
Several of these trials were completed last year and this year. None have
shown strong positive results yet. Note that there was one very big and
positive trial completed about four years ago showing beneficial effects of
daily aspirin on stroke incidence and severity, primary in men and younger
women. If you look at the journal Stroke, they publish yearly a complete
roundup of all clinical stroke trials in the United States.
Wise Young, NYU Medical Center.